The Archive · 3 posts

Scancell Holdings Plc

Innovative cancer solutions! 🔬 Scancell Holdings Plc (SCLP) leads in immunotherapies, traded on LSE. A biotech game-changer! 🚀

SubscribeRSS JSON

Scancell Results: Phase 3 Progress Meets a Major Funding Test

Scancell is preparing for a Phase 3 melanoma trial, but funding remains conditional and its accounts contain a going-concern warning.

October 9, 2026

Trending

Browse All

Investing

Scancell targets Nasdaq with Neuphoria merger and up to $89 million funding package

Scancell's proposed Neuphoria merger could unlock Nasdaq access and fund Phase 3 development, but dilution and execution risks are substantial.

JoshuaJuly 23, 2026

Investing

Scancell Reports Positive Phase 2 Data and Financial Results for FY 2025

Scancell's iSCIB1+ shows 78% 11-month PFS in advanced melanoma, with Modi-1 signals and cash runway into H2 2026. Key Phase 2 data and financial results.

JoshuaSeptember 11, 2025

Got an investment you want to share?

Let's Go